Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.370 -0.220 (-3.34%)
Streaming Delayed Price Updated: 2:05 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
39 40 Next >
Allied, ATAI Life Sciences Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 5.27% at $0.76 
Via Benzinga
Research Finds That Mushrooms May Have Their Own Language
Via Investor Brand Network
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 8.17% at $9.80 
Via Benzinga
April Update: Most Cannabis Categories Declined By More Than 20%
The marijuana stock sector consists of 5 distinct categories and they each performed quite differently from one another in April.. 
Via Talk Markets
Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 3.67% at $0.57 LOSERS: 
Via Benzinga
Vancouver Island University to Expand Psychedelic Mental Healthcare Program
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 28, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 4.35% at $1.20 
Via Benzinga
BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape
Via Investor Brand Network
Colorado Patients Reap Benefits of Ketamine Treatments for Depression
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages
Via Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in... 
Via FinancialNewsMedia
Topics Derivatives ETFs
Exposures Derivatives
Psychedelic Stock Gainers And Losers From April 27, 2022
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.77% at $0.28 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.61% at $0.29 
Via Benzinga
Psychedelic Drug Patenting: Still Only Scratching The Surface
Psychedelic drug R&D remains in its infancy, with dozens of psychedelics and several 
Via Talk Markets
Depression Causes Lasting Physiological Alterations to Immunity Cells
Via Investor Brand Network
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97 
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Three Kinds of Trauma Psychedelics Hope to Treat
Via Investor Brand Network
Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference
Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87 
Via Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) To Present At KCSA Psychedelics Conference
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference
Via Investor Brand Network
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 20.83% at $0.29 
Via Benzinga
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
Via Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.